Showing 1 - 6 results of 6 for search 'Christopher D. Herzog', query time: 0.02s Refine Results
  1. 1
    Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease

    Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease by Shilpa Ramaswamy, Jodi L. McBride, Christopher D. Herzog, Eugene Brandon, Mehdi Gasmi, Raymond T. Bartus, Jeffrey H. Kordower

    Published 2007-05-01
    Get full text
    Article
  2. 2
    Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

    Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease by Raymond T. Bartus, Lamar Brown, Alistair Wilson, Brian Kruegel, Joao Siffert, Eugene M. Johnson, Jr., Jeffrey H. Kordower, Christopher D. Herzog

    Published 2011-10-01
    Get full text
    Article
  3. 3
    Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

    Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120) by Christopher D. Herzog, Lamar Brown, Brian R. Kruegel, Alistair Wilson, Malú G. Tansey, Fred H. Gage, Eugene M. Johnson, Jr., Raymond T. Bartus

    Published 2013-10-01
    Get full text
    Article
  4. 4
    Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal

    Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal by Ilana Moscatelli, Elena Almarza, Axel Schambach, David Ricks, Ansgar Schulz, Christopher D. Herzog, Kim Henriksen, Maria Askmyr, Jonathan D. Schwartz, Johan Richter

    Published 2021-03-01
    Get full text
    Article
  5. 5
    Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease

    Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease by Shilpa Ramaswamy, Jodi L. McBride, Ina Han, Elizabeth M. Berry-Kravis, Lili Zhou, Christopher D. Herzog, Mehdi Gasmi, Raymond T. Bartus, Jeffrey H. Kordower

    Published 2009-04-01
    Get full text
    Article
  6. 6
    AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

    AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease by Mehdi Gasmi, Eugene P. Brandon, Christopher D. Herzog, Alistair Wilson, Kathie M. Bishop, Eva K. Hofer, Justine J. Cunningham, Marie A. Printz, Jeffrey H. Kordower, Raymond T. Bartus

    Published 2007-07-01
    Get full text
    Article

Search Tools: